Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Next Previous
Trial Profile

A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosmidomycin (Primary) ; Piperaquine
  • Indications Falciparum malaria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FOSPIP
  • Sponsors Jomaa Pharma

    • Most Recent Events

    • 26 Dec 2017 Primary endpoint (Per protocol, PCR-corrected cure rate on Day 28) has been met as per the results published in the Clinical Infectious Diseases
    • 26 Dec 2017 Results assessing safety and efficacy published in the Clinical Infectious Diseases
    • 14 Nov 2016 According to Jomaa Pharma media release, scientific paper on this study was presented at the 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top